Cns Pharmaceuticals Inc (CNSP) — 13F Holders Deep Dive (Q2 2026)

CNSP ranks #9856 out of 37527 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

11 institutions disclose a position in CNSP, but none treat it as a major bet — even Stonepine Capital Management, LLC, its most concentrated holder, allocates just 3.0% of its own portfolio to it.

CNSP is down 2.4% today, but institutions show net buying of $7.0M this quarter — a divergence between today's price move and the underlying institutional flow.

CNSP reported a net loss of $15.9M in its latest fiscal year.

• Not yet profitable — net loss of $15.9M in the latest fiscal year
• Net income declined year over year, from -$14.9M to -$15.9M
• Operating cash flow was negative, using $13.8M in cash
• Current ratio of 1.98x — enough short-term assets to cover short-term liabilities
• Total liabilities currently exceed total assets (negative shareholder equity)